CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Protagonist Therapeutics Swings to Q3 Net Income of $220.02 Million

By Public Technologies
  • Protagonist Therapeutics swung to third-quarter 2026 net income of $220.02 million from a year-earlier loss.
  • License and collaboration revenue rose to $274.41 million, primarily driven by $266.6 million in proportional recognition of Takeda payments.
  • FDA approval of MIMRYLO for erythrocytosis in adults with polycythemia vera triggered $275 million in payments.
  • The board authorized repurchases of up to $300 million of outstanding common stock in September.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611051605ACCESSWRNAPR_____1247425) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk